In response to concerns about inappropriate testing and healthcare costs, cliniciansand laboratorians should work together to evaluate laboratory tests. Studies of routine laboratory tests ordered for screening and case-finding in the preoperative setting, at hospital admission, and in the ambulatory setting have not provided sufficient evidence of the benefits of case-finding when evaluated against commonly used criteria for screening procedures. We adapt a conceptual framework developed from radiology for evaluating imaging technologies to evaluate laboratory tests. The framework addresses diagnostic efficacy (whether the test correctly identifies abnormalities), diagnostic effectiveness (whether the test changes the physician's diagnoses), therapeutic efficacy (whether the test changes patient management), and therapeutic effectiveness (whether the test changes patients' outcomes). We propose that clinicians and laboratorians use this framework to evaluate the diagnostic efficacy, diagnostic effectiveness, therapeutic efficacy, and therapeutic effectiveness of laboratory tests in the ambulatory setting and in other settings. We are now moving beyond an era of cost containment to the "third revolution" in medical care, the era of accountability (1). and are useful in designing a conceptual framework for evaluating laboratory tests (2). Screening is the application of tests and procedures to large unselected populations; people identifled to have a high risk are then advised to consult their own physician for further evaluation. Case-finding is the application of a test or procedure by a physician or healthcare worker to a specific patient to detect an unsuspected condition that is unrelated to the problem for which the patient is being seen; the healthcare worker who ordered the test is responsible for further evaluation. The terms screening and case-finding are often used interchangeably, but are not identical concepts. Case-finding more accurately describes test ordering in the ambulatory setting. Screening and case-finding are both aimed at classifying people into two groups: one with a high probability of a fatal or disabling condition and the other with a low probability of a fatal or disabling condition.
In response to concerns about inappropriate testing and healthcare costs, cliniciansand laboratorians should work together to evaluate laboratory tests. Studies of routine laboratory tests ordered for screening and case-finding in the preoperative setting, at hospital admission, and in the ambulatory setting have not provided sufficient evidence of the benefits of case-finding when evaluated against commonly used criteria for screening procedures. We adapt a conceptual framework developed from radiology for evaluating imaging technologies to evaluate laboratory tests. The framework addresses diagnostic efficacy (whether the test correctly identifies abnormalities), diagnostic effectiveness (whether the test changes the physician's diagnoses), therapeutic efficacy (whether the test changes patient management), and therapeutic effectiveness (whether the test changes patients' outcomes). We propose that clinicians and laboratorians use this framework to evaluate the diagnostic efficacy, diagnostic effectiveness, therapeutic efficacy, and therapeutic effectiveness of laboratory tests in the ambulatory setting and in other settings. We are now moving beyond an era of cost containment to the "third revolution" in medical care, the era of accountability (1). The second level, diagnostic accuracy efficacy, describes yield, sensitivity, specificity, and positive and negative predictive values of a laboratory test in the clinical setting. Next, diagnostic thinking efficacy addresses the issue of whether the diagnostic test changes the thinking of the clinician. Fourth, therapeutic efficacy, addresses whether a test result changes the clinical management of the patient, whereas patient outcome efficacy, the fifth level, describes the outcomes that patients actually experience.
Finally, societal efficacy addresses issues such as the health of the population and the costs of tests. The Fryback and Thornbury framework can be applied to any type of test ordered for any indication.
After review of relevant issues and available data in the evaluation of routine laboratory tests, we will propose a modification of the framework to also take into account the intended management plan, not just the management initiated.
Current Issues in Evaluating Laboratory Tests
In the evaluation of routine laboratory tests in ambulatory patients, clinicians and laboratorians must address whether tests are ordered appropriately as well as the issue of the costs of laboratory tests. Physicians generally report that laboratory tests are helpful and result in a change in diagnosis, therapy, and prognosis, or in their understanding of the patient's disease (7).
Informally, however, physicians may mention inappropriate reasons for ordering tests (8). Periodically the medical literature contains reports of inappropriate test ordering (9, 10), reflecting the concern that in clinical practice many laboratory tests are obtained for reasons that would not withstand careful critical review. When medical care costs are evaluated, the analysis usually focuses on the high-cost decisions: e.g., the decision to admit a patient to the hospital, the decision to admit to intensive care, the decision to admit to a nursing home, the decision to operate, and the decision to use life-sustaining therapy. These inpatient decisions are all characterized by important clinical events in the care of individual patients. These decisions are often referred to as "big-ticket" items. Medical care costs, however, result not only from the use of high-cost procedures, but also from the high volume use of low-cost tests. These "little-ticket" items often escape attention because they are less visible in the course of care of an individual patient. In addition, because of their high volume of use, they are accepted as being customary and 16 years, compared with 5557 health plan members who otherwise received usual care but no annual screening, reported no differences in disability or total mortality, and no benefits attributed to any findings of the routine multichannel laboratory tests. Similar disappointing results of routine laboratory tests were noted in another trial of multiphasic screening. A clinical controlled trial of multiphasic screening in 574 families in Salt Lake City in the 1970s, designed to identify differences in utilization of health services, morbidity, and health status, found that routine tests did not change morbidity or health status. The only significant difference was increased hospitalization among screened subjects (27).
New guIdelines
Recently, the value of laboratory screening tests in the ambulatory setting has been studied in a university clinic in Basel, Switzerland.
In a prospective study of an unselected cohort of 493 newly evaluated ambulatory patients, a 23-test biochemistry panel, including a lipid proffle, was routinely obtained for each subject (28). The mean age of these patients was 41 years; 43% were female, and only 8% were older than 60. Results for 1162 (11%) of 10 190 routine tests were abnormal; however, the overall yield was only 32 new diagnoses, of which 25 were treated: hyperlipidemia (22 cases), alcoholic liver disease (2), and hypocalcemia (1). Thus only 25 of 493 patients (4%) benefited from case-finding, as judged by the initiation of some form of treatment, mainly through screening for hyperlipidemia. The value of four tests from the complete blood count (hemoglobin, mean erythrocyte volume, leukocyte count, and platelet count) for case-finding was also analyzed in an unselected cohort of 595 adults from the same clinic (29). Anomalies were detected in 6% of routine tests. The overall yield was five diagnoses without treatment and only three new diagnoses with treatment, all microcytic anemia from benign conditions. In summary, these two recent studies from Basel found that only 0.2% of the routine tests resulted in a change in patient management. In this setting (mostly a young male population), the value of the biochemistry panel was mainly related to the yield of the lipid tests; the complete blood count had no value.
A retrospective descriptive
review of 100 patients who had a comprehensive general medical examination at the Mayo Clinic in 1991 was recently undertaken to help plan a prospective study of routine ambulatory test ordering (Boland et al., ms. submitted for publication). Fifty patients from the local community and 50 patients from the referral practice were studied. The biochemistry profile, lipids, complete blood count, thyroid hormone concentrations, and urinalysis were evaluated as routine case-finding tests. The proportion of patients for whom these routine tests were used for case-finding ranged from 83% (thyroid tests) to 98% (complete blood counts). (Table 3) . None of the three expert panels The Fryback and Thornbury framework uses only the term efficacy. We believe it would be helpful to clarify the difference between efficacy and effectiveness in the framework.
Further, the framework should take into account both diagnostic thinking and intended management plan in addition to the diagnoses made and the management initiated. Therefore, we propose a framework with four levels-diagnostic efficacy, diagnostic effectiveness, therapeutic efficacy, and therapeutic effectiveness--with two components each ( and cost of care. Societal outcomes include analyses of the impact of diagnostic testing on the health and function of members of the community and on societal costs, i.e., both the economic costs of providing services and the noneconomic costs, including lost productivity.
The framework in Table 4 is a revision of the important innovative work by Fiyback and Thornbuiy. Our framework uses both efficacy and effectiveness to describe different levels, simplifies the number of levels, and explicitly addresses the impact of tests in changing the intended and actual diagnoses and in changing the intended and actual management.
Further, it provides a ready mapping to Donabedian's conceptual framework for quality in healthcare, which includes structure (diagnostic efficacy), process (diagnostic effectiveness and therapeutic efficacy), and outcomes (therapeutic effectiveness)
(36).
In conclusion, medicine is currently experiencing a paradigm shift away from the principle of"do no harm," under which we have the technolor and resources to order tests provided we are not harming our patients, to a new paradigm exhorting us to "do what works," conthin costs, and measure outcomes.
As physicians and laboratorians we must evaluate our current practices before external forces oblige us to change our practice and then evaluate the impact of these changes. We need to change our clinical and laboratory practices on the basis of evidence for the effectiveness of laboratory tests in the clinical setting. To respond to this era of change, we must study the performance of laboratory tests in the ambulatory setting, continually monitor patient outcomes, and adapt our practice to the needs of society.
